178 related articles for article (PubMed ID: 37742015)
1. Modeled small airways lung deposition of two fixed-dose triple therapy combinations assessed with in silico functional respiratory imaging.
Usmani O; Li G; De Backer J; Sadafi H; Wu L; Marshall J
Respir Res; 2023 Sep; 24(1):226. PubMed ID: 37742015
[TBL] [Abstract][Full Text] [Related]
2. Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT.
Stolz D; Hermansson E; Ouwens M; Singh B; Sharma A; Jackson D; Darken P; Marshall J; Bowen K; Müllerová H; Alcázar Navarrete B; Russell R; Han MK; Tansey-Dwyer D
Curr Med Res Opin; 2023 Oct; 39(10):1395-1405. PubMed ID: 37583267
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
4. Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simulations.
Usmani OS; Scichilone N; Mignot B; Belmans D; Van Holsbeke C; De Backer J; De Maria R; Cuoghi E; Topole E; Georges G
Int J Chron Obstruct Pulmon Dis; 2020; 15():2433-2440. PubMed ID: 33116458
[TBL] [Abstract][Full Text] [Related]
5. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
[TBL] [Abstract][Full Text] [Related]
6. A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Usmani O; Roche N; Wahab E; Israel S; Jenkins M; Trivedi R; Dorinsky P; Aurivillius M
Respir Res; 2021 Oct; 22(1):261. PubMed ID: 34620167
[TBL] [Abstract][Full Text] [Related]
7. Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids.
van den Berge M; De Backer J; Van Holsbeke C; De Backer W; Trivedi R; Jenkins M; Dorinsky P; Aurivillius M
Respir Res; 2021 Jul; 22(1):191. PubMed ID: 34210340
[TBL] [Abstract][Full Text] [Related]
8. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
[TBL] [Abstract][Full Text] [Related]
9. Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study.
Singh D; Rabe KF; Martinez FJ; Krüll M; Jenkins M; Patel M; Dorinsky P
Respir Med; 2022 Jun; 197():106857. PubMed ID: 35512458
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts.
Muro S; Sugiura H; Darken P; Dorinsky P
Respir Res; 2021 Jun; 22(1):187. PubMed ID: 34182998
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Small Airways with Inhaled Corticosteroid/Long-Acting Beta Agonist Dry Powder Inhalers: A Functional Respiratory Imaging Study.
Watz H; Barile S; Guastalla D; Topole E; Cocconi D; Mignot B; Belmans D; Duman D; Poli G; Fabbri LM
J Aerosol Med Pulm Drug Deliv; 2021 Sep; 34(5):280-292. PubMed ID: 33944614
[No Abstract] [Full Text] [Related]
12. Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS.
Bafadhel M; Rabe KF; Martinez FJ; Singh D; Darken P; Jenkins M; Aurivillius M; Patel M; Dorinsky P
Int J Chron Obstruct Pulmon Dis; 2022; 17():3061-3073. PubMed ID: 36510486
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study.
de Nigris E; Treharne C; Brighton N; Holmgren U; Walker A; Haughney J
Int J Chron Obstruct Pulmon Dis; 2022; 17():2987-3000. PubMed ID: 36444374
[TBL] [Abstract][Full Text] [Related]
14. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.
Darken P; DePetrillo P; Reisner C; St Rose E; Dorinsky P
Pulm Pharmacol Ther; 2018 Jun; 50():11-18. PubMed ID: 29544728
[TBL] [Abstract][Full Text] [Related]
16. Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler
Rabe KF; Martinez FJ; Singh D; Trivedi R; Jenkins M; Darken P; Aurivillius M; Dorinsky P
Ther Adv Respir Dis; 2021; 15():17534666211034329. PubMed ID: 34428980
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary deposition of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler formulated using co-suspension delivery technology in healthy male subjects.
Israel S; Kumar A; DeAngelis K; Aurivillius M; Dorinsky P; Roche N; Usmani OS
Eur J Pharm Sci; 2020 Oct; 153():105472. PubMed ID: 32682074
[TBL] [Abstract][Full Text] [Related]
18. Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease Using Functional Respiratory Imaging: An
Usmani OS; Mignot B; Kendall I; Maria R; Cocconi D; Georges G; Scichilone N
J Aerosol Med Pulm Drug Deliv; 2021 Jun; 34(3):204-211. PubMed ID: 33052749
[No Abstract] [Full Text] [Related]
19. Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler.
Van Holsbeke C; De Backer J; Vos W; Marshall J
Ther Adv Respir Dis; 2018; 12():1753466618760948. PubMed ID: 29499614
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
